In a nutshell This study explored the effects of different second-line therapies combined with metformin (Glucophage) in patients with type 2 diabetes (T2D). The data showed that metformin combinations with a sulfonylurea (SU) had the lowest weight loss, the smallest effect of lowering blood glucose, and an overall, reduced health...
Read More
In a nutshell This study evaluated the outcomes of cotadutide (MEDI0382) treatment in patients with type 2 diabetes (T2D) and obesity. This study concluded that cotadutide treatment improved glycemic (blood sugar) control and weight loss in these patients. Some background T2D is commonly associated with obesity. About 70% of patients with T2D...
Read More
In a nutshell In this study, the authors evaluated the effectiveness of adding dapagliflozin (Farxiga) to insulin therapy in patients with uncontrolled type 2 diabetes (T2D). The study showed that compared to increasing insulin doses, dapagliflozin improved glucose control while reducing weight and hypoglycemia (dangerously low blood...
Read More
In a nutshell This study looked at how weekly semaglutide (Ozempic) affected patients with type 2 diabetes (T2D) in a real-world setting. It found that semaglutide improved blood sugar control compared to the treatments patients were already taking. Some background For patients with T2D, the body does not respond well to the hormone insulin, which...
Read More
In a nutshell This study compared the effectiveness and safety of biphasic insulin aspart 30 (BIAsp 30; NovoMix 30) alone or with metformin (Glucophage), in patients with inadequately controlled type 2 diabetes (T2D). The authors concluded that combined therapy may be preferred in patients with high cardiovascular risk and/or a body...
Read More
In a nutshell This study examined the effectiveness of adding henagliflozin (SHR3824) to metformin (Glucophage) in patients with uncontrolled type 2 diabetes (T2D). The authors concluded that the addition of 5 mg or 10 mg of henagliflozin to metformin was well-tolerated and effective in these patients. Some background...
Read More
In a nutshell This study looked at the ertugliflozin (Steglatro) for patients with type 2 diabetes (T2D) and heart disease. It found that ertugliflozin improved both blood glucose control, body weight, and blood pressure. Some background T2D is a condition in which the levels of glucose (sugar) in the blood are too high. T2D is related to...
Read More
In a nutshell This study compared the safety and effectiveness of liraglutide (Victoza) to insulin glargine (Lantus) on glycemic (blood glucose) control in patients with type 2 diabetes (T2D) after hospital discharge. The authors concluded that liraglutide treatment led to improved glycemic control and greater weight loss compared to...
Read More
In a nutshell This study looked at the effect of bariatric surgery (BS; weight loss surgery) on complications of type 2 diabetes (T2D). It found that patients who had BS had fewer vision, foot, and kidney complications. Some background Diabetes is a long-lasting health condition that involves high levels of sugar in the blood. Over time, high blood...
Read More
In a nutshell This study tested the ability of henagliflozin (SHR3824) in controlling blood glucose levels in patients with type 2 diabetes (T2D). The authors found that henagliflozin alone was able to control glucose levels, reduce body weight and blood pressure in these patients. Some background Insulin is a hormone produced by the...
Read More
In a nutshell This review compared the effects of two types of bariatric surgery (weight loss surgery) on type 2 diabetes (T2D) remission over five years. It found that Roux-en-Y gastric bypass (RYGB) led to better diabetes outcomes than sleeve gastrectomy (SG). It also found that both types of surgery led to improvements in T2D. Some background T2D...
Read More
In a nutshell This study compared the safety of two medications, linagliptin (Trajenta) and glimepiride (Amaryl). It found that the medications had the same risk of heart attack, stroke, or heart-related death, while linagliptin was associated with a lower risk of hypoglycemia (dangerously low blood glucose level). Some background There...
Read More
